전신전이를 동반한 비부비동 점막 흑색종의 면역치료 1예
A Case of Metastatic Sinonasal Mucosal Melanoma Treated with Immunotherapy
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Sinonasal mucosal melanoma (SMM) is rare form of melanoma and accounts for 4%-13% of all sinonasal malig- nant tumor. SMM is characterized by aggressive growth with high locoregional recurrence and distant metastasis. Immunotherapy has been known as effective therapeutic strategies in metastatic melanoma. Immune checkpoint inhibitors; anticytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and antigrogrammed cell death 1 (PD-1), demonstrated the improved prognosis in advanced malignant melanoma. Recently, authors experienced a case of SMM patient with locoregional and distance metastasis, who was successfully treated with anti-PD-1 mono- clonal antibody. We report a case of metastatic malignant melanoma with literature review.
Abstract
Sinonasal mucosal melanoma (SMM) is rare form of melanoma and accounts for 4%-13% of all sinonasal malig- nant tumor. SMM is characterized by aggressive growth with high locoregional recurrence and distant metastasis. Immunotherapy has been known as effective therapeutic strategies in metastatic melanoma. Immune checkpoint inhibitors; anticytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and antigrogrammed cell death 1 (PD-1), demonstrated the improved prognosis in advanced malignant melanoma. Recently, authors experienced a case of SMM patient with locoregional and distance metastasis, who was successfully treated with anti-PD-1 mono- clonal antibody. We report a case of metastatic malignant melanoma with literature review.
참고문헌 (20)
- Meerwein CM, "Current concepts in advanced sinonasal mucosal melanoma : a single institution experience", Eur Arch Otorhinolaryngol, 276(8), pp.2259~2265 (2019)
- Postow MA, "Mucosal melanoma : pathogenesis, clinical behavior, and management", Curr Oncol Rep, 14(5), pp.441~448 (2012)
- Mihajlovic M, "Primary mucosal melanomas : a comprehensive review", Int J Clin Exp Pathol, 5(8), pp.739~753 (2012)
- Atrash S, "Response of metastatic mucosal melanoma to immunotherapy : it can get worse before it gets better", J Oncol Pharm Pract, 23(3), pp.215~219 (2017)
- Studentova H, "Immunotherapy in mucosal melanoma : a case report and review of the literature", Oncotarget, 9(25), pp.17971~17977 (2018)
- Roth TN, "Outcome of sinonasal melanoma : clinical experience and review of the literature", Head Neck, 32(10), pp.1385~1392 (2010)
- Sun CZ, "Treatment and prognosis in sinonasal mucosal melanoma : a retrospective analysis of 65 patients from a single cancer center", Head Neck, 36(5), pp.675~681 (2014)
- Choubey D, "Type I interferon(IFN)-inducible Absent in Melanoma 2 proteins in neuroinflammation : implications for Alzheimer’s disease", J Neuroinflammation, 16(1), pp.236~ (2019)
- Coventry BJ, "Therapeutic vaccination immunomodulation : forming the basis of all cancer immunotherapy", Ther Adv Vaccines Immunother, 7, pp.2515135519862234~ (2019)
- Chen C, "Th17 cells paradoxical roles in melanoma and potential application in immunotherapy", Front Immunol, 10, pp.187~ (2019)
- Ralli M, "Immunotherapy in the treatment of metastatic melanoma : current knowledge and future directions", J Immunol Res, 2020, pp.9235638~ (2020)
- Larkin J, "Combined nivolumab and ipilimumab or monotherapy in untreated melanoma", N Engl J Med, 373(13), pp.1270~1271 (2015)
- Wolchok JD, "Overall survival with combined nivolumab and ipilimumab in advanced melanoma", N Engl J Med, 377(14), pp.1345~1356 (2017)
- Min L, "Anti-PD1 following ipilimumab for mucosal melanoma : durable tumor response associated with severe hypothyroidism and rhabdomyolysis", Cancer Immunol Res, 2(1), pp.15~18 (2014)
- D’Angelo SP, "Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma : a pooled analysis", J Clin Oncol, 35(2), pp.226~235 (2017)
- Hodi FS, "Improved survival with ipilimumab in patients with metastatic melanoma", N Engl J Med, 363(8), pp.711~723 (2010)
- Rodríguez-Lomba E, "Vitiligo-like lesions and immune checkpoint inhibition therapy: is it truly an adverse event exclusive to patients with melanoma?", Clin Exp Dermatol, 43(5), pp.598~599 (2018)
- Trinh S, "Management of immune-related adverse events associated with immune checkpoint inhibitor therapy : a minireview of current clinical guidelines", Asia Pac J Oncol Nurs, 6(2), pp.154~160 (2019)
- Teulings HE, "Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival : a systematic review and meta-analysis", J Clin Oncol, 33(7), pp.773~781 (2015)
- Dréno M, "Sinonasal mucosal melanoma : a 44-case study and literature analysis", Eur Ann Otorhinolaryngol Head Neck Dis, 134(4), pp.237~242 (2017)